Compare Enveric Biosciences Inc (ENVB) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Union Pacific Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Union Pacific Corporation trades at $277.88 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 24304.4× Enveric Biosciences Inc's market cap, and Union Pacific Corporation pays a 2.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Union Pacific Corporation for 105 Days on average.
| ENVB | UNP | |
|---|---|---|
Market Cap | $6.80M | $165.27B |
Volume | 64,867 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $10.80 | $310.62 |
52-Week Low | $1.27 | $216.37 |
Typical Hold Time | 14 Days | 105 Days |
Enterprise Value | -$1.49M | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Union Pacific (UNP) trades at $274.68, down 0.7% today, with a bearish technical signal despite strong Q2 2026 earnings beat. The stock shows robust fundamentals with 28.85% net margin and 39.7% ROE, supported by $9.3B operating cash flow in 2025. Recent news highlights battery-electric locomotive deployment and momentum in the Norfolk Southern combination, while analyst consensus remains bullish with a $332.10 price target.
UNP presents a compelling long-term investment with strong profitability and dividend growth, though near-term technical weakness and merger uncertainty pose risks. The stock trades at a discount to analyst targets, offering potential upside if operational execution continues and the Norfolk Southern deal progresses favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
